Literature DB >> 23265554

Diagnostic criteria for neurocysticercosis, revisited.

Oscar H Del Brutto1.   

Abstract

Diagnosis of neurocysticercosis (NCC) can be a challenge. Clinical manifestations are non-specific, most neuroimaging findings are non-pathognomonic, and some serologic tests have low sensitivity or specificity. A set of diagnostic criteria was proposed in 2001 to avoid the over diagnosis of NCC that occurs in epidemiologic surveys, and to help clinicians evaluating patients with suspected NCC. The set included four stratified categories of criteria, including: (1) absolute: histological demonstration of cysticerci, cystic lesions showing the scolex on neuroimaging studies, and direct visualization of subretinal parasites by fundoscopic examination; (2) major: lesions highly suggestive of NCC on neuroimaging studies, positive serum enzyme-linked immunoelectrotransfer blot (EITB) for the detection of anticysticercal antibodies, resolution of intracranial cystic lesions after cysticidal drug therapy, and spontaneous resolution of single enhancing lesions; (3) minor: lesions compatible with NCC on neuroimaging studies, suggestive clinical manifestations, positive cerebrospinal fluid (CSF) ELISA for detection of anticysticercal antibodies or cysticercal antigens, and cysticercosis outside the nervous system; and (4) epidemiological: evidence of a household contact with Taenia solium infection, individuals coming from or living in cysticercosis endemic areas, and history of travel to disease-endemic areas. Interpretation of these criteria permits two degrees of diagnostic certainty: (1) definitive diagnosis, in patients who have one absolute criterion or in those who have two major plus one minor and one epidemiological criteria; and (2) probable diagnosis, in patients who have one major plus two minor criteria, in those who have one major plus one minor and one epidemiological criteria, and in those who have three minor plus one epidemiological criteria. After 10 years of usage, this set has been proved useful in both, field studies, and hospital settings. Recent advances in neuroimaging and immune diagnostic methods have enhanced its accuracy for the diagnosis of NCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265554      PMCID: PMC4005113          DOI: 10.1179/2047773212Y.0000000025

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  36 in total

1.  Neurocysticercosis in Australia: still free of autochthonous cases?

Authors:  Oscar H Del Brutto
Journal:  Med J Aust       Date:  2012-04-02       Impact factor: 7.738

Review 2.  Immunodiagnosis of Taenia solium taeniosis/cysticercosis.

Authors:  Nynke Deckers; Pierre Dorny
Journal:  Trends Parasitol       Date:  2010-01-18

3.  Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991-2008).

Authors:  Curtis Croker; Roshan Reporter; Laurene Mascola
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

4.  A diagnostic and therapeutic scheme for a solitary cysticercus granuloma.

Authors:  G Singh; V Rajshekhar; J M K Murthy; S Prabhakar; M Modi; N Khandelwal; H H Garcia
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

Review 5.  Proposed diagnostic criteria for neurocysticercosis.

Authors:  O H Del Brutto; V Rajshekhar; A C White; V C Tsang; T E Nash; O M Takayanagui; P M Schantz; C A Evans; A Flisser; D Correa; D Botero; J C Allan; E Sarti; A E Gonzalez; R H Gilman; H H García
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

6.  Single small enhancing CT lesion in Thai patients with acute symptomatic seizures: a clinico-radiological study.

Authors:  P Yodnopaklow; A Mahuntussanapong
Journal:  Trop Med Int Health       Date:  2000-04       Impact factor: 2.622

Review 7.  Neurocysticercosis among international travelers to disease-endemic areas.

Authors:  Oscar H Del Brutto
Journal:  J Travel Med       Date:  2012-02-24       Impact factor: 8.490

8.  Serologic diagnosis of human Taenia solium cysticercosis by using recombinant and synthetic antigens in QuickELISA™.

Authors:  Yeuk-Mui Lee; Sukwan Handali; Kathy Hancock; Sowmya Pattabhi; Victor A Kovalenko; Andrew Levin; Silvia Rodriguez; Sehching Lin; Christina M Scheel; Armando E Gonzalez; Robert H Gilman; Hector H Garcia; Victor C W Tsang
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

Review 9.  A review of cases of human cysticercosis in Canada.

Authors:  Oscar H Del Brutto
Journal:  Can J Neurol Sci       Date:  2012-05       Impact factor: 2.104

10.  Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid.

Authors:  Lorraine Michelet; Agnès Fleury; Edda Sciutto; Eric Kendjo; Gladis Fragoso; Luc Paris; Bernard Bouteille
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

View more
  42 in total

1.  Imaging and Serological-Evidence of Neurocysticercosis Among Patients with Seizures in Odisha, an Unexplored Eastern Coastal Province in India.

Authors:  Priyadarshi Soumyaranjan Sahu; Shubhransu Patro; Payod Kumar Jena; Santosh Kumar Swain; Bidyut Kumar Das
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 2.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

3.  The Lack of Association of Eosinophilia and Neurocysticercosis at Clinical Presentation: A Retrospective Analysis of Cases Seen at the National Institutes of Health, 1985-2015.

Authors:  JeanAnne M Ware; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

4.  Parenchymal neurocysticercosis.

Authors:  Zaw Min
Journal:  Intern Emerg Med       Date:  2014-06-03       Impact factor: 3.397

5.  Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform.

Authors:  Jay S Hanas; James R Hocker; Govindan Ramajayam; Vasudevan Prabhakaran; Vedantam Rajshekhar; Anna Oommen; Josephine J Manoj; Michael P Anderson; Douglas A Drevets; Hélène Carabin
Journal:  Exp Parasitol       Date:  2018-08-08       Impact factor: 2.011

6.  Neurocysticercosis in Bhutan: a cross-sectional study in people with epilepsy.

Authors:  Kate Brizzi; Sonam Pelden; Tshokey Tshokey; Damber K Nirola; Megan B Diamond; Joshua P Klein; Lhab Tshering; Sonam Deki; Dechen Nidup; Veronica Bruno; Pierre Dorny; Hector Hugo Garcia; Farrah J Mateen
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-09       Impact factor: 2.184

7.  Blood-brain barrier disruption and angiogenesis in a rat model for neurocysticercosis.

Authors:  Rogger P Carmen-Orozco; Danitza G Dávila-Villacorta; Yudith Cauna; Edson G Bernal-Teran; Leandra Bitterfeld; Graham L Sutherland; Nancy Chile; Rensson H Céliz; María C Ferrufino-Schmidt; Cesar M Gavídia; Charles R Sterling; Héctor H García; Robert H Gilman; Manuela Renee Verástegui
Journal:  J Neurosci Res       Date:  2018-10-13       Impact factor: 4.164

8.  Anti-Taenia solium monoclonal antibodies for the detection of parasite antigens in body fluids from patients with neurocysticercosis.

Authors:  Adriana Paredes; Patricia Sáenz; Miguel W Marzal; Miguel A Orrego; Yesenia Castillo; Andrea Rivera; Siddhartha Mahanty; Cristina Guerra-Giraldez; Hector H García; Theodore E Nash
Journal:  Exp Parasitol       Date:  2016-03-23       Impact factor: 2.011

Review 9.  Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.

Authors:  Rumana Ahmad; Tahmeena Khan; Bilal Ahmad; Aparna Misra; Anil K Balapure
Journal:  Parasitol Res       Date:  2016-10-24       Impact factor: 2.289

10.  Diethylaminoethyl (DEAE) binding fraction from Taenia solium metacestode improves the neurocysticercosis serodiagnosis.

Authors:  Vanessa da S Ribeiro; Daniela da S Nunes; Henrique T Gonzaga; Jair P da Cunha-Junior; Julia M Costa-Cruz
Journal:  Parasitol Res       Date:  2014-04-29       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.